Skip to main content

Phase 3-results for MOB-015 published in JAAD

STOCKHOLM, June 10[th] 2021. Moberg Pharma AB (OMX: MOB) announces that the results from the North American phase 3-study with MOB-015 (topical terbinafine) for the treatment of onychomycosis have been published in the Journal of the American Academy of Dermatology.

In December 2019, Moberg Pharma announced positive top-line results from a phase 3-study including 365 patients, where the primary efficacy endpoint and the two key secondary efficacy endpoints were met. Mycological cure was achieved in 70 percent of patients receiving MOB-015 and complete cure was achieved in 4.5 percent of patients receiving MOB-015. Treatment success (mycological cure and almost or completely clear great toenail) assessed by the investigator was achieved in 15.4 percent of the patients. In the patients’ self-assessments, a clear majority (83 percent) of the patients completing the study reported improvement from MOB-015 as early as 12 weeks after starting treatment, and at week 52, 33 percent reported their treated toenails were cured or almost cured. Both physician´s and patient´s assessment were consistent in showing that the high mycological cure rate achieved with treatment with MOB-015 translated into clinical benefit. The results are now published in the Journal of the American Academy of Dermatology, Volume 85, Issue 1, July 2021, Pages 95-104 and are available online.

For the full article, see:

For additional information, please contact:
Anna Ljung, CEO, telephone: +46 707 66 60 30, e-mail:

Amir Tavakkol, Chief Scientific Officer, telephone: +1 (973) 307 4856, e-mail:

About this information
The information was submitted for publication, through the agency of the contact person set out above, at 8.00 a.m. (CET) on June 10th 2021.

About Moberg Pharma,
Moberg Pharma AB (publ) is a Swedish pharmaceutical company focused on commercializing proprietary innovations based on drug delivery of proven compounds. The company’s main asset, MOB-015, is a novel topical treatment for onychomycosis. Data from phase 3 clinical trials in more than 800 patients for MOB-015 indicate that the product has the potential to become the future market leader in onychomycosis. Moberg Pharma has agreements with commercial partners in place in Europe and Japan, among others, and the company's intention is to submit a registration application during the second half of 2021 in Europe. Moberg Pharma is headquartered in Stockholm and the company’s shares are listed on the Small Cap list of the Nasdaq Stockholm (OMX: MOB).